{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T10:14:35Z","timestamp":1771668875436,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1093\/annonc\/mdy254","type":"journal-article","created":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T12:18:06Z","timestamp":1531570686000},"page":"2302-2312","source":"Crossref","is-referenced-by-count":11,"title":["Novel therapies in urothelial carcinoma: a biomarker-driven approach"],"prefix":"10.1016","volume":"29","author":[{"given":"G.","family":"Iyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdy254_bb0010","unstructured":"American Cancer Society: Cancer Facts and Figures 2017. Atlanta, GA: American Cancer Society, 2017. https:\/\/old.cancer.org\/acs\/groups\/content\/@editorial\/documents\/document\/acspc-048738.pdf"},{"key":"10.1093\/annonc\/mdy254_bb0015","author":"Hurwitz","year":"2016"},{"issue":"12","key":"10.1093\/annonc\/mdy254_bb0020","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s10552-016-0821-7","article-title":"Smoking status, usual adult occupation, and risk of recurrent urothelial bladder carcinoma: data from The Cancer Genome Atlas (TCGA) Project","volume":"27","author":"Wilcox","year":"2016","journal-title":"Cancer Causes Control"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdy254_bb0025","doi-asserted-by":"crossref","first-page":"iii40","DOI":"10.1093\/annonc\/mdu223","article-title":"Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Bellmunt","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy254_bb0030","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mdy254_bb0035","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1093\/annonc\/mdy254_bb0040","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy254_bb0045","article-title":"Palliative chemotherapy for bladder cancer: treatment delivery and outcomes in the general population","author":"Robinson","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdy254_bb0050","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy254_bb0055","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cncr.22454","article-title":"Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function","volume":"109","author":"Galsky","year":"2007","journal-title":"Cancer"},{"issue":"25","key":"10.1093\/annonc\/mdy254_bb0060","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1200\/JCO.2008.21.2241","article-title":"Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium","volume":"27","author":"Milowsky","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy254_bb0065","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.clgc.2013.11.022","article-title":"Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate\/vinblastine\/doxorubicin\/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer","volume":"12","author":"Necchi","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1093\/annonc\/mdy254_bb0070","doi-asserted-by":"crossref","unstructured":"JE Rosenberg, E Heath, R Perez et al. Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC). Poster Presented at ESMO 2016; Abstr #788.","DOI":"10.1093\/annonc\/mdw373.16"},{"issue":"3","key":"10.1093\/annonc\/mdy254_bb0075","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy254_bb0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/mdv509","article-title":"Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis","volume":"27","author":"Raggi","year":"2016","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy254_bb0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.juro.2015.06.115","article-title":"Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond-a comprehensive review of the current literature","volume":"195","author":"Oing","year":"2016","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdy254_bb0090","unstructured":"Javlor (vinflunine) SmPC. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000983\/WC500039604.pdf"},{"key":"10.1093\/annonc\/mdy254_bb0095","unstructured":"TECENTRIQ\u00ae (atezolizumab) PI. https:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf"},{"issue":"10031","key":"10.1093\/annonc\/mdy254_bb0100","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdy254_bb0105","unstructured":"Tecentriq Approval History, 2017. https:\/\/www.drugs.com\/history\/tecentriq.html"},{"issue":"10122","key":"10.1093\/annonc\/mdy254_bb0110","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdy254_bb0115","unstructured":"Opdivo (nivolumab) PI. http:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf"},{"key":"10.1093\/annonc\/mdy254_bb0120","unstructured":"P Sharma, MK Callahan, E Calvo et al. Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: first results from the phase I\/II CheckMate 032 study. Presented at 2016 SITC Annual Meeting; 9\u201313 November 2016, National Harbor, MD, Abstr #O3."},{"issue":"11","key":"10.1093\/annonc\/mdy254_bb0125","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdy254_bb0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1093\/annonc\/mdy254_bb0135","doi-asserted-by":"crossref","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy254_bb0140","article-title":"Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study","volume":"28","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdy254_bb0145","doi-asserted-by":"crossref","unstructured":"T Powles, P Grivas, JB Aragon-Ching et al. A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100). Poster Presented at ESMO 2016, Abstr #842.","DOI":"10.1093\/annonc\/mdw373.69"},{"key":"10.1093\/annonc\/mdy254_bb0150","article-title":"Planned survival analysis from KEYNOTE-045 Phase 3 open-label study of pembrolizumab (pembro) versus paclitaxel docetaxel or vinflunine in recurrent advanced urothelial cancer","author":"Bajorin","year":"2017","journal-title":"(UC) Presented at 2017 ASCO Congress"},{"issue":"11","key":"10.1093\/annonc\/mdy254_bb0155","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1093\/annonc\/mdy254_bb0160","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy254_bb0165","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1093\/annonc\/mdy254_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9020015","article-title":"Systemic immunotherapy for urothelial cancer: current trends and future directions","volume":"9","author":"Gupta","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1093\/annonc\/mdy254_bb0175","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/0008-5472.CAN-09-3562","article-title":"The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer","volume":"70","author":"Smith","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdy254_bb0180","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1593\/neo.101214","article-title":"Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents","volume":"13","author":"Smith","year":"2011","journal-title":"Neoplasia"},{"issue":"32","key":"10.1093\/annonc\/mdy254_bb0185","doi-asserted-by":"crossref","first-page":"13086","DOI":"10.1073\/pnas.0610292104","article-title":"A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery","volume":"104","author":"Lee","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1093\/annonc\/mdy254_bb0190","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.clgc.2015.10.002","article-title":"Sacituzumab govitecan, a novel antibody\u2013drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma","volume":"14","author":"Faltas","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdy254_bb0195","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/s41467-017-02320-7","article-title":"Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"issue":"12","key":"10.1093\/annonc\/mdy254_bb0200","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdy254_bb0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J Pathol"},{"issue":"4","key":"10.1093\/annonc\/mdy254_bb0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2017.11","article-title":"The evolving genomic landscape of urothelial carcinoma","volume":"14","author":"Glaser","year":"2017","journal-title":"Nat Rev Urol"},{"issue":"34","key":"10.1093\/annonc\/mdy254_bb0215","doi-asserted-by":"crossref","first-page":"55924","DOI":"10.18632\/oncotarget.10482","article-title":"FGFR3-TACC3 fusion in solid tumors: mini review","volume":"7","author":"Costa","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1093\/annonc\/mdy254_bb0220","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"30","key":"10.1093\/annonc\/mdy254_bb0225","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy254_bb0230","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdy254_bb0235","article-title":"Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1\u20133 inhibitor, in patients (pts) with previously treated advanced\/metastatic urothelial carcinoma (mUC) with FGFR3 alterations","volume":"34","author":"Pal","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdy254_bb0240","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2018.36.15_suppl.4503","article-title":"First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)","volume":"36","author":"Siefker-Radtke","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy254_bb0245","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1464-410X.2012.11720.x","article-title":"Phase II study of everolimus in metastatic urothelial cancer","volume":"112","author":"Milowsky","year":"2013","journal-title":"BJU Int"},{"issue":"10","key":"10.1093\/annonc\/mdy254_bb0250","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1093\/annonc\/mds057","article-title":"Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers","volume":"23","author":"Seront","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy254_bb0255","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000376551","article-title":"Second-line treatment of advanced urothelial cancer with paclitaxel and everolimus in a German phase II trial (AUO Trial AB 35\/09)","volume":"89","author":"Niegisch","year":"2015","journal-title":"Oncology"},{"issue":"1","key":"10.1093\/annonc\/mdy254_bb0260","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3233\/BLC-150038","article-title":"Phase I study of everolimus in combination with gemcitabine and split-dose cisplatin in advanced urothelial carcinoma","volume":"2","author":"Abida","year":"2016","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdy254_bb0265","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","article-title":"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov"},{"issue":"6104","key":"10.1093\/annonc\/mdy254_bb0270","doi-asserted-by":"crossref","first-page":"221.","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"issue":"6","key":"10.1093\/annonc\/mdy254_bb0275","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.eururo.2015.01.015","article-title":"Exceptional response on addition of everolimus to taxane in urothelial carcinoma bearing an NF2 mutation","volume":"67","author":"Ali","year":"2015","journal-title":"Eur Urol"},{"issue":"7492","key":"10.1093\/annonc\/mdy254_bb0280","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"13","key":"10.1093\/annonc\/mdy254_bb0285","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.24337","article-title":"A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma","volume":"115","author":"W\u00fclfing","year":"2009","journal-title":"Cancer"},{"issue":"Suppl","key":"10.1093\/annonc\/mdy254_bb0290","article-title":"A phase II\/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1\/2 positive metastatic bladder cancer patients","volume":"33","author":"Powles","year":"2015","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1093\/annonc\/mdy254_bb0295","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2015.66.3047","article-title":"Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations","volume":"34","author":"Choudhury","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10064","key":"10.1093\/annonc\/mdy254_bb0300","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"10.1093\/annonc\/mdy254_bb0305","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, Phase 1b study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdy254_bb0310","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdy254_bb0315","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdy254_bb0320","article-title":"A phase 3 study of first-line durvalumab (MEDI4736) \u00b1 tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): dANUBE","volume":"34","author":"Powles","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9178","key":"10.1093\/annonc\/mdy254_bb0325","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(99)02292-8","article-title":"Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists","volume":"354","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"10.1093\/annonc\/mdy254_bb0330","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","author":"Advanced Bladder Collaboration (ABC) Meta-analysis Collaboration","year":"2005","journal-title":"Eur Urol"},{"issue":"9","key":"10.1093\/annonc\/mdy254_bb0335","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1093\/annonc\/mdy254_bb0340","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical Validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1093\/annonc\/mdy254_bb0345","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1093\/annonc\/mdy254_bb0350","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdy254_bb0355","article-title":"DNA damage repair and response (DDR) gene alterations (alt) and response to PD1\/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC)","volume":"35","author":"Teo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdy254_bb0360","article-title":"Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B)","volume":"35","author":"Carlo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"49","key":"10.1093\/annonc\/mdy254_bb0365","doi-asserted-by":"crossref","first-page":"80164","DOI":"10.18632\/oncotarget.13284","article-title":"Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer","volume":"7","author":"Ochoa","year":"2016","journal-title":"Oncotarget"},{"issue":"6 Suppl","key":"10.1093\/annonc\/mdy254_bb0370","article-title":"Muscle-invasive bladder cancer: molecular subtypes and response to neoadjuvant chemotherapy","volume":"35","author":"Seiler","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdy254_bb0375","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody\u2013drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"Suppl","key":"10.1093\/annonc\/mdy254_bb0380","article-title":"Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)","volume":"36","author":"Rosenberg","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdy254_bb0385","article-title":"Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC)","volume":"34","author":"Petrylak","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy254_bb0390","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1369\/0022155411410430","article-title":"Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target","volume":"59","author":"Stepan","year":"2011","journal-title":"J Histochem Cytochem"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419342292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419342292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/12\/2302\/31190877\/mdy254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/12\/2302\/31190877\/mdy254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T07:26:49Z","timestamp":1720423609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419342292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":77,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0923753419342292"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy254","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}